FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Described is a method of identifying infectious mononucleosis associated with Epstein-Barr virus, characterized by the fact that peripheral blood leukocytes detect level of 5 AR transcript expression, ASCC1 4 transcript, CAD gene, FADD mRNA, 2 HLA-DPA1 transcript 2 and RIPK1 4 transcript and while reducing 5 AR transcript, ASCC1 transcript 4, CAD gene, mRNA FADD and increased expression of transcript 2 HLA-DPA1 and transcript 4 RIPK1 identify infectious mononucleosis associated with Epstein-Barr virus.
EFFECT: invention can be used for studying molecular mechanisms of pathogenesis, as well as for clinical diagnosis and monitoring of the disease.
1 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF INFECTIOUS MONONUCLEOSIS OF VARIOUS AETIOLOGY | 2019 |
|
RU2707077C1 |
| BIOMARKERS OF DEVELOPING COMPLICATIONS OF INFECTIOUS MONONUCLEOSIS ASSOCIATED WITH EPSTEIN-BARR VIRUS | 2019 |
|
RU2720110C1 |
| METHOD OF SEARCHING FOR MOLECULAR MARKERS OF A PATHOLOGICAL PROCESS FOR DIFFERENTIAL DIAGNOSIS, MONITORING AND TARGETED THERAPY | 2019 |
|
RU2709815C1 |
| DIAGNOSTIC TECHNIQUE FOR SEVERE FORM OF THE EBV-ASSOCIATED INFECTIOUS MONONUCLEOSIS | 2020 |
|
RU2732012C1 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING WEB-ASSOCIATED TUMORS IN THE PATIENTS WITH ACUTE EBV-INFECTION | 2019 |
|
RU2707075C1 |
| METHOD FOR IDENTIFYING INFECTIOUS MONONUCLEOSIS ASSOCIATED WITH TYPE 6 HUMAN HERPES VIRUS | 2019 |
|
RU2729413C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF HERPES VIRUS MIXED INFECTION | 2020 |
|
RU2739854C1 |
| METHOD FOR PREDICTION OF SEVERITY OF EBV-ASSOCIATED INFECTIOUS MONONUCLEOSIS | 2020 |
|
RU2732010C1 |
| METHOD FOR DETECTION OF GENOTYPES 1 AND 2 OF EPSTEIN-BARR VIRUS | 2022 |
|
RU2789353C1 |
| METHOD OF ASSESSING THE SEVERITY OF ACUTE INFECTIOUS MONONUCLEOSIS CAUSED BY THE EPSTEIN-BARR VIRUS IN CHILDREN | 2022 |
|
RU2798079C1 |
